| Document |
Document Title |
|
WO/2020/239025A1 |
The present subject matter contemplates small molecule, fluorescent compounds having aggregation-induced emission (AIE) characteristics. The compounds can exhibit emission in the second near-infrared window (NIR-II) (1000 nm-1700 nm). Th...
|
|
WO/2020/239074A1 |
A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.
|
|
WO/2020/243153A1 |
The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV inf...
|
|
WO/2020/239999A1 |
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventin...
|
|
WO/2020/239517A1 |
Mesoionic imidazolium compounds of formula (I) and their uses for combating animal pests. The present invention relates to compounds of formula (I), wherein A, W, Y, T and R1 are defined as in the description, and to the stereoisomers, s...
|
|
WO/2020/232655A1 |
Presented is an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic elect...
|
|
WO/2020/237169A1 |
Disclosed herein are compounds, compositions, and methods for inhibiting a histone methyltransferase. The compounds are verticillin derivatives that exhibit anti-proliferative activity against cancer cells. The compounds, compositions, a...
|
|
WO/2020/234483A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
|
WO/2020/237063A1 |
A compound with the following general formula (I) and a general method of making this compound are provided. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are each independently selected from the group that includes H, h...
|
|
WO/2020/221380A1 |
The present invention provides a structurally novel class of heterocyclic compounds of general formula I wherein L1 is heteroaryl and L2 is heteroaryl or aryl. The novel compounds are useful in a method of prevention or treatment of a co...
|
|
WO/2020/210339A1 |
The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amou...
|
|
WO/2020/200284A1 |
Provided are a tricyclic small molecule compound, a preparation method therefor, a pharmaceutical composition containing said compound, and use thereof in medicine. Said compound is used as a bromodomain protein 4 (BRD4) inhibitor, and c...
|
|
WO/2020/204402A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic layer placed between the first electrode and the second electrode;...
|
|
WO/2020/205867A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2020/201991A1 |
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoi...
|
|
WO/2020/201096A1 |
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they ...
|
|
WO/2020/191503A1 |
Methods and uses of bromantane and derivatives of the Formula (Ia) or (Ib) for treating fibrotic diseases are taught, and in particular, chronic lung disease, including idiopathic pulmonary fibrosis; non-alcoholic fatty liver disease, an...
|
|
WO/2020/193447A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2020/198058A1 |
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
|
|
WO/2020/187865A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2020/180127A1 |
The present invention relates to a novel compound having excellent electron transport ability and luminescence, and an organic electroluminescent device which comprises same in one or more organic layers and thus has improved characteris...
|
|
WO/2020/169804A1 |
Compounds of formula (I), wherein A, Z, E, R1, R2, m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
|
WO/2020/167976A1 |
Described herein are compounds that regulate pyruvate kinase activity, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R2, L1-L2, U1-U7, m, ring A, and Q are as defined herein.
|
|
WO/2020/167984A1 |
Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compoun...
|
|
WO/2020/161209A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2020/161208A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2020/157652A2 |
This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to phar...
|
|
WO/2020/158870A1 |
The purpose in one embodiment of the present invention is to provide a therapeutic for Parkinson's disease, etc. A compound represented by formulas (1), (2), or (8) or a pharmacologically acceptable salt thereof can be used in the treatm...
|
|
WO/2020/156243A1 |
Provided is a compound for use as an inhibitor of Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) (as represented by formula I), and pharmaceutical composition and preparation method thereof, and use thereof in the...
|
|
WO/2020/152132A1 |
The invention relates to thiazolopyridine derivatives which fall under the general formula I, (I) and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and ...
|
|
WO/2020/153432A1 |
The present invention addresses the problem of providing a compound that is useful as an active ingredient for preventing and treating inflammatory diseases and that has a chemical structure to function as a specific antedrug having an e...
|
|
WO/2020/153431A1 |
The present invention addresses the problem of providing a compound that is useful as an active ingredient for preventing and treating inflammatory diseases and that has a chemical structure to function as a specific antedrug having an e...
|
|
WO/2020/153433A1 |
The present invention addresses the problem of providing a compound that is useful as an active ingredient for preventing and treating inflammatory diseases and that has a specific chemical structure having an effect of activating SIRT6....
|
|
WO/2020/150417A2 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/147802A1 |
Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are a...
|
|
WO/2020/143798A1 |
The invention relates to an internal cyclic sulphiamidine amide-aryl amide compound and a use thereof for treating hepatitis B. Specifically, disclosed is a compound that may act as an HBV replication inhibitor and that has a structure r...
|
|
WO/2020/141478A1 |
The present invention provides novel thiazolyl peptide compounds and their pharmaceutically acceptable salts either alone or in combinations with Rifampicin, Amikacin and Clarithromycin against infections caused by Nontuberculous mycobac...
|
|
WO/2020/138015A1 |
The present invention provides: a novel compound that is useful for treating or preventing infections associated with viruses belonging to the subfamily Pneumovirinae, including respiratory syncytial virus (RSV), and that has an anti-RSV...
|
|
WO/2020/135439A1 |
A deuterated dihydropyrimidine compound and use thereof as a drug, especially as a drug for treating and preventing hepatitis B. In particular, the present invention relates to a compound represented by general formula (I) or (Ia) or a s...
|
|
WO/2020/125729A1 |
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
|
|
WO/2020/126591A1 |
The present invention relates to substituted pyrimidinium compounds of formula (I), to the stereoisomers, salts, tautomers and N-oxides thereof and to compositions comprising such compounds. The invention also relates to methods and uses...
|
|
WO/2020/127960A1 |
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
|
|
WO/2020/127735A1 |
This invention is directed to improved processes for the preparation of (2-amino-4-[6-(4-fluorophenyl)-2-[(4-methyl-1-piperazinyl)me
thyl]imidazo[2,1-b]thiazol-5-yl]-pyrimidine of Formula (I).
|
|
WO/2020/127765A1 |
The present invention is directed to crystalline phosphate salts of 5,6-diarylimidazo[2,1-b][1,3]thiazoles of Formula (I) or a solvate or hydrate thereof, wherein R = NH2 or H; A = CH or N; R' = CH2-1-Me-piperazin-4-yl or CH2NMe2; X = F,...
|
|
WO/2020/125730A1 |
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
|
|
WO/2020/130681A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising same. As the compound according to the present invention is used in an organic material layer of an organic electroluminescent device, ...
|
|
WO/2020/132381A1 |
The present invention relates to co-crystals of the compound of formula (I), wherein the co-former molecule is succinic acid or citric acid, processes for the preparation of the co-crystal, pharmaceutical compositions thereof, and method...
|
|
WO/2020/123850A1 |
The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of adm...
|
|
WO/2020/121823A1 |
The present invention addresses the problem of providing: a liquid crystal composition which is to be used in an active drive display element and improves chromatic dispersion properties; a display element which uses said liquid crystal ...
|
|
WO/2020/111613A1 |
The present invention provides a novel compound and an organic light-emitting diode using same.
|
